GlobeNewswire Inc.··Not SpecifiedAcrivon's AP3 Platform Shows Promise: ACR-368 Synergies Highlighted at AACR 2026
Acrivon Therapeutics presents preclinical data at AACR 2026 demonstrating strong synergy between its CHK1/2 and WEE1 inhibitors with ADC payloads and immunotherapies.
ACRVendometrial cancerAACR Annual Meeting